| Literature DB >> 35789894 |
Imane Motaib1, Fatima-Zahra Rhmari Tlemçani1, Mohamed Khalis2, Soukaina Laidi1, Saloua Elamari1, Asma Chadli1.
Abstract
Background: The management of diabetes during Ramadan is well codified. International guidelines recommend avoiding fasting for patients with the risk of complications. However, during Ramadan drastic changes occur in lifestyles habits. Our study aims to evaluate the impact of the month of Ramadan on the lifestyle habits and metabolic profile of non-fasting patients with diabetes. Patients andEntities:
Keywords: Ramadan; diabetes; metabolic profile; non-fasting patients
Year: 2022 PMID: 35789894 PMCID: PMC9250316 DOI: 10.2147/DMSO.S354627
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.249
Baseline Characteristics of Patients: Demographics, Diabetes History and Risk Stratification
| Characteristics | Median (IQR) or N (%) | |
|---|---|---|
| Age (years) | 64 (57.5–71.0) | |
| Gender | Male | 94 (60.6) |
| Female | 61 (39.4) | |
| Duration of diabetes (%) | >10 years | 56 (36.1) |
| < 10 years | 99 (63.9) | |
| Type of diabetes (%) | Type 1 | 11 (6.5) |
| Type 2 | 144 (93.5) | |
| HTN* (%) | 90 (58.1) | |
| Degenerative complications (%) | No complications | 42 (27.1) |
| Microangiopathies | 55 (36.1) | |
| Macroangiopathies | 24 (15.5) | |
| Combined | 33 (21.3) | |
| Risk stratification (IDF) (%) | High risk | 14 (8.4) |
| Very high risk | 141 (91.6) | |
| Insulin therapy (%) | No insulin | 34 (21.9) |
| Basal | 33 (21.9) | |
| Basal-bolus | 49 (31.6) | |
| Pre-mixed | 38 (24.5) | |
| Oral anti-diabetics (%) | No OAD** | 76 (49.4) |
| Metformin | 39 (25.3) | |
| MTF***+sitagliptin | 24 (15.6) | |
| MTF+empagliflozine | 8 (5.2) | |
| MTF+ gliclazide | 4 (2.6) | |
| MTF+sitagliptin+gliclazide | 3 (1.9) |
Notes: *Hypertension, **Oral anti-diabetics, ***Metformin.
Baseline Characteristics of Patients: Anthropometric and Metabolic Parameters, and Caloric Intake of Patients
| Characteristics | Median (IQR) or N (%) | |
|---|---|---|
| Weight (kg) | 77 (69–88) | |
| BMI*Before ramadan (kg/m2) | 28 (24.9–31.9) | |
| Waist circumference (cm) | 99 (91–105) | |
| HbA1c (%) | 8.45 (7.7–10) | |
| FBG** (g/l) | 1.8 (1.4–2.09) | |
| TC#(g/l) | 1.7 (1.32–2.01) | |
| LDL## (g/l) | 1.01 (0.74–1.32) | |
| TG† (g/l) | 1.2 (0.95–1.6) | |
| Caloric intake (Kcal) | 1641 (1454–1915) | |
| GPAQ score (%) | 1 | 130 (83.9) |
| 2 | 18 (11.6) | |
| 3 | 7 (4.5) |
Notes: *Body mass index. **Fasting blood glucose, #Total cholesterol, ##Low-density lipoprotein cholesterol, †Triglycerides.
Comparison of Caloric Intake, Physical Activity Level, Anthropometric and Metabolic Parameters Before and After Ramadan in All Non-Fasting Patients with Diabetes
| Variable | Before Ramadan - Median (IQR) or N (%) | During/ After Ramadan - Median (IQR) or N (%) | p-value |
|---|---|---|---|
| Weight (kg) | 77 (69–88) | 78 (70–89.8) | < 0.001 |
| BMI* (kg/m2) | 28 (24.9–31.9) | 28 (24.9–32.6) | < 0.001 |
| Waist circumference (cm) | 99 (91–105) | 98 (92–107) | < 0.001 |
| HbA1c (%) | 8.45 (7.7–10) | 8.55 (7.5–10) | < 0.001 |
| LDL-C** (g/l) | 1.1 (0.74–1.32) | 1.01 (1.38–2.22) | 0.061 |
| TG***(g/l) | 1.31 (0.95–1.6) | 1.39 (0.95–1.6) | < 0.001 |
| Caloric intake (kcal) | 1659.48 (340.631) | 1861.78 (497.238) | < 0.001 |
| Number of meals | 4 (3–4) | 4 (3–4) | 0.75 |
| GPAQ score | |||
| 1 | 83.9 | 83.4 | 0.791 |
| 2 | 11.6 | 12.6 | |
| 3 | 4.5 | 4 | |
Notes: *Body mass index, **Low-density lipoprotein cholesterol, ***Triglycerides.
Figure 1Evolution of anthropometric and metabolic parameters among non-fasting patients during Ramadan.
Comparison of Caloric Intake, Anthropometric and Metabolic Parameters Before and After Ramadan in Patients’ Insulin Therapy and in Patients in Oral Antidiabetic Drugs
| Patients in Insulin Therapy | Patients in Oral Anti-Diabetic Agents | |||||
|---|---|---|---|---|---|---|
| Weight (kg) | 79.30 (68.5–88.0) | 80.78 (70.1–90.0) | 0.001 | 78.56 (69.9–87.2) | 78.35 (69.7–87.2) | 0.72 |
| BMI* (kg/m2) | 28.43 (24.0–32.0) | 28.65 (24.6–33.0) | 0.008 | 28.76 (26.0–32.0) | 28.62 (25.8–31.2) | 0.81 |
| Waist circumference (cm) | 98.46 (89–106) | 99.4 (91.5–108) | 0.003 | 98.74 (91.00–101.5) | 98.88 (91.75–106.00) | 0.76 |
| HbA1c (%) | 9.23 (8.0–10.0) | 9.08 (8.0–10.0) | 0.67 | 8.15 (7.0–8.55) | 8.03 (7.00–9.00) | 0.90 |
| LDL-C** (g/l) | 1.04 (1.0–1.0) | 1.18 (1.0–1.0) | 0.008 | 0.95 (0.95–1.0) | 0.96 (0.88–1.00) | 0.90 |
| TG# (g/l) | 1.34 (1.0–2.0) | 1.41 (1.0–2.0) | 0.57 | 1.35 (1.0–2.0) | 1.34 (1.00–2.00) | 0.90 |
| Caloric intake (kcal) | 1666.29 (1453.2–1915) | 1881.66 (1560.0–2288.0) | <0.0001 | 1635.3 (1474.7–1801.4) | 1791.9 (1452.0–2232.0) | 0.004 |
Notes: *Body mass index, **Low-density lipoprotein cholesterol, #Triglycerides.